Objective: This real-world large cohort study was aimed to compare effect of moderate intensity atorvastatin and ezetimibe combination therapy and high intensity atorvastatin therapy on cardiovascular events and diabetes in patients with angina pectoris undergoing percutaneous coronary intervention (PCI).

Methods: This retrospective cohort study used Korean National Health Insurance Data. Study participants underwent PCI between 2015 and 2018, and received high-intensity atorvastatin (atorvastatin 40-80 mg; n = 2,102) or moderate-intensity atorvastatin (atorvastatin 10-20 mg) plus ezetimibe (n = 4,682). The primary outcome was each cardiovascular outcome; incidence of cardiovascular death, myocardial infarction (MI) and stroke. The secondary outcome was newly developed diabetes.

Results: During a mean follow up of 4 years, there were no significant differences in the cardiovascular outcomes between high-intensity atorvastatin monotherapy and moderate-intensity atorvastatin and ezetimibe combination therapy. The adjusted hazard ratio (aHR) for cardiovascular death was 1.18 [95% confidence interval (CI): 0.87-1.61, p=0.285], MI was 0.82 (95% CI 0.67-1.01; p = 0.066). and stroke was 1.10 (95% CI: 0.86-1.39, p=0.453), respectively. The risk of new onset diabetes was not different between the two-treatment group (aHR: 0.99, 95% CI: 0.88-1.13, p=0.94).

Conclusions: There was no significant difference in the cardiovascular outcome and risk of new onset diabetes between high-intensity atorvastatin monotherapy and moderate-intensity atorvastatin and ezetimibe combination therapy, in real-world large cohort study.

Disclosure

S. Sohn: None. S. Cho: None.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.